| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
To investigate the effect of Dasatinib, a tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukemia, on an experimental in vitro proliferative vitreoretinopathy (PVR) models.We tested Dasatinib using in vitro PVR model.
Dasatinib significantly prevented the enlargement of RPE sheet in a concentration dependent manner. Reduced expression of S100A4 by immunohistochemical staining on cultured RPE sheets confirmed suppression of EMT by Dasatinib. Proliferative membrane in group 3 strongly expressed α-SMA compared with group 1 and group 2 at day 6. Dasatinib inhibited Collagen gel contraction in group 1 and group 2. On the other hand, shrinkage of collagen gel was not suppressed in group 3 with dense fibrosis, despite the addition of Dasatinib.Dasatinib significantly inhibited prevented membrane contraction in PVR model at early stage.
|
